Maximum quantity allowed is 999
Please select the quantity
CAS RN: 190791-29-8 | Product Number: L0336
Lasofoxifene Tartrate
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol Tartrate
- Oporia
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days |
|---|---|---|---|
| 10MG |
$87.00
|
16 | 1 |
| 50MG |
$338.00
|
28 | 15 |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | L0336 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__8H__3__1NO__2·C__4H__6O__6 = 563.65 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Hygroscopic,Heat Sensitive |
| CAS RN | 190791-29-8 |
| Reaxys Registry Number | 14771789 |
| PubChem Substance ID | 468592153 |
| MDL Number | MFCD30207839 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 185 °C(dec.) |
GHS
Related Laws:
| RTECS# | QK4252964 |
Transport Information:
| H.S.code* | 2933.99-000 |
Application
Lasofoxifene tartrate: A Third-Generation, Non-Steroidal Selective Estrogen Receptor Modulator (SERM)
Lasofoxifene tartrate (CP-336156) is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). SERMs have the ability to provide mixed functional estrogen receptor (ER) agonist or antagonist activity, depending on the target tissue. Lasofoxifene has a remarkably improved oral bioavailability with respect to other SERMs, selectively binds to both ERα and ERβ with high affinity, and acts as a tissue selective estrogen antagonist or agonist.1-3) It has been reported that lasofoxifene prevents estrogen deficiency-induced bone loss, inhibits breast tumor formation and reduces serum cholesterol. In clinical, lasofoxifene tartrate has been used for the treatment of osteoporosis4) and breast cancer.5,6) (The product is for research purpose only.)
References
- 1) Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus, and body composition in rat models
- 2) Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene
- 3) Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat
- 4) Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis (a review)
- 5) Preventive therapy for breast cancer: a consensus statement (a review)
- 6) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice (a review)
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.